• 1
    Fleming S, Lewi HJ. Collecting duct carcinoma of the kidney. Histopathology 1986; 10: 113141.
  • 2
    Dimopoulos MA, Logothetis CJ, Markowitz A, Sella A, Amato R, Ro J. Collecting duct carcinoma of the kidney. Br J Urol 1993; 71: 38891.
  • 3
    Kennedy SM, Merino MJ, Linehan WM, Roberts JR, Robertson CN, Neumann RD. Collecting duct carcinoma of the kidney. Hum Pathol 1990; 21: 44956.
  • 4
    Carter MD, Tha S, McLoughlin MG, Owen DA. Collecting duct carcinoma of the kidney: a case report and review of the literature. J Urol 1992; 147: 10968.
  • 5
    Fukuya T, Honda H, Goto K, Ono M, Matsuura T, Kaneko K, et al. Computed tomographic findings of Bellini duct carcinoma of the kidney. J Comput Assist Tomogr 1996; 20: 399403.
  • 6
    Dodd PM, McCaffrey JA, Hilton S, Mazumadar M, Herr H, Kelly WK, et al. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J Clin Oncol 2000; 18: 8406.
  • 7
    Masson P. In: Kobernick S, translator. Tumeurs humaines: human tumors, histology, diagnosis and technique. 2nd edition. Detroit: Wayne State University Press, 1955.
  • 8
    Mancilla-Jimenez R, Stanley RJ, Blath RA. Papillary renal cell carcinoma: a clinical, radiologic and pathologic study of 34 cases. Cancer 1976; 38: 246980.
  • 9
    Fuzesi L, Cober M, Mittermayer C. Collecting duct carcinoma: cytogenetic characterization. Histopathology 1992; 21: 15560.
  • 10
    Steiner G, Cairns P, Polascik TJ, Marshall FF, Epstein JI, Sidransky D, et al. High-density mapping of chromosomal arm 1q in renal collecting duct carcinoma: region of minimal deletion at 1q32.1-32.2. Cancer Res 1996;56: 50446.
  • 11
    Fogt F, Zhuang Z, Linehan WM, Merino MJ. Collecting duct carcinomas of the kidney: a comparative loss of heterozygosity study with clear cell renal cell carcinoma. Oncol Rep 1998; 5: 9236.
  • 12
    Schoenberg M, Cairns P, Brooks JD, Marshall FF, Epstein JI, Isaacs WB, et al. Frequent loss of chromosome arms 8p and 13q in collecting duct carcinoma (CDC) of the kidney. Genes Chromosomes Cancer 1995; 12: 7680.
  • 13
    Takle LA, Knowles MA. Deletion mapping implicates two tumor suppressor genes on chromosome 8p in the development of bladder cancer. Oncogene 1996; 12: 1087.
  • 14
    Selli C, Amorosi A, Vona G, Sestini R, Travaglini F, Bartoletti R, et al. Retrospective evaluation of c-erbB-2 oncogene amplification using competitive PCR in collecting duct carcinoma of the kidney. J Urol 1997; 158: 2457.
  • 15
    von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, phase III study. J Clin Oncol 2001; 18: 306877.
  • 16
    Maluf FC, Hilton S, Nanus DM, Herr H, Mazumdar M, Higgins G, et al. Sequential doxorubicin/gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. Proc ASCO 2000: 19: 3422.